Posted by Michael Wonder on 18 Dec 2025
Alnylam announces Health Canada approval of Amvuttra (vutrisiran), the first and only RNAi therapeutic for the treatment of cardiomyopathy in adult patients with ATTR amyloidosis
16 December 2025 - Alnylam Canada is pleased to announce that Health Canada has issued a Notice of Compliance authorising Amvuttra (vutrisiran) for the treatment of cardiomyopathy in adult patients with wild-type or hereditary transthyretin-mediated amyloidosis (wtATTR or hATTR amyloidosis).
The approval broadens the indication for Amvuttra, which now becomes the first and only RNAi therapeutic authorised by Health Canada for the treatment of both the cardiomyopathy manifestations of TTR amyloidosis and stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis.
